Provided by Tiger Fintech (Singapore) Pte. Ltd.

Apogee Therapeutics

47.46
+3.147.08%
Post-market: 47.500.0400+0.08%16:20 EDT
Volume:506.85K
Turnover:23.51M
Market Cap:2.77B
PE:-13.22
High:47.71
Open:44.71
Low:43.51
Close:44.32
Loading ...

Apogee Therapeutics' Chief Medical Officer Carl Dambkowski Reports Disposal of Common Shares

Reuters
·
04 Jul

Apogee Therapeutics Price Target Maintained With a $116.00/Share by Guggenheim

Dow Jones
·
02 Jul

Buy Rating for Apogee Therapeutics: High Potential of APG777 in Atopic Dermatitis with Mitigated Risks

TIPRANKS
·
24 Jun

Apogee Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
23 Jun

TD Cowen Sticks to Its Buy Rating for Apogee Therapeutics (APGE)

TIPRANKS
·
11 Jun

Apogee Therapeutics' Chief Medical Officer Carl Dambkowski Reports Disposal of Common Shares

Reuters
·
07 Jun

Apogee Therapeutics Reports Q1 2025 Progress and Financials

TIPRANKS
·
13 May

Why Is Apogee Therapeutics Stock Trading Higher On Monday?

Benzinga
·
13 May

Apogee Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
13 May

Apogee Therapeutics: Promising Biologics Developments Justify Buy Rating

TIPRANKS
·
13 May

Apogee Therapeutics Q1 EPS $(0.95) Beats $(1.25) Estimate

Benzinga
·
12 May

Apogee Therapeutics Reports Positive Phase 1b Trial Results

TIPRANKS
·
12 May

Apogee Therapeutics Q1 Loss Widens

MT Newswires Live
·
12 May

Earnings Flash (APGE) Apogee Therapeutics Posts Q1 Net Loss $55.3M, vs. FactSet Est of $72.3M Loss

MT Newswires Live
·
12 May

Apogee Therapeutics Cash, Cash Equivalents And Marketable Securities Were $681.4M As Of March 31, 2025 That Supports Runway Into Q1 2028

Benzinga
·
12 May

Press Release: Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results

Dow Jones
·
12 May

Apogee Therapeutics Inc. Chief Medical Officer Carl Dambkowski Reports Disposal of Common Shares

Reuters
·
10 May

Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference

GlobeNewswire
·
01 May

Companies Like Apogee Therapeutics (NASDAQ:APGE) Are In A Position To Invest In Growth

Simply Wall St.
·
23 Apr

Apogee Therapeutics price target lowered to $78 from $80 at BofA

TIPRANKS
·
08 Apr